Widjaja Ivy, Wicht Oliver, Luytjes Willem, Leenhouts Kees, Rottier Peter J M, van Kuppeveld Frank J M, Haijema Bert Jan, de Haan Cornelis A M
Virology Division, Department of Infectious Diseases & Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands
Mucosis B.V., Meditech Center, Groningen, The Netherlands.
J Virol. 2016 Jun 10;90(13):5965-5977. doi: 10.1128/JVI.00235-16. Print 2016 Jul 1.
Antibodies against the fusion (F) protein of respiratory syncytial virus (RSV) play an important role in the protective immune response to this important respiratory virus. Little is known, however, about antibody levels against multiple F-specific epitopes induced by infection or after vaccination against RSV, while this is important to guide the evaluation of (novel) vaccines. In this study, we analyzed antibody levels against RSV proteins and F-specific epitopes in human sera and in sera of vaccinated and experimentally infected cotton rats and the correlation thereof with virus neutralization. Analysis of human sera revealed substantial diversity in antibody levels against F-, G (attachment)-, and F-specific epitopes between individuals. The highest correlation with virus neutralization was observed for antibodies recognizing prefusion-specific antigenic site Ø. Nevertheless, our results indicate that high levels of antibodies targeting other parts of the F protein can also mediate a potent antiviral antibody response. In agreement, sera of experimentally infected cotton rats contained high neutralizing activity despite lacking antigenic site Ø-specific antibodies. Strikingly, vaccination with formalin-inactivated RSV (FI-RSV) exclusively resulted in the induction of poorly neutralizing antibodies against postfusion-specific antigenic site I, although antigenic sites I, II, and IV were efficiently displayed in FI-RSV. The apparent immunodominance of antigenic site I in FI-RSV likely explains the low levels of neutralizing antibodies upon vaccination and challenge and may play a role in the vaccination-induced enhancement of disease observed with such preparations.
RSV is an importance cause of hospitalization of infants. The development of a vaccine against RSV has been hampered by the disastrous results obtained with FI-RSV vaccine preparations in the 1960s that resulted in vaccination-induced enhancement of disease. To get a better understanding of the antibody repertoire induced after infection or after vaccination against RSV, we investigated antibody levels against fusion (F) protein, attachment (G) protein, and F-specific epitopes in human and animal sera. The results indicate the importance of prefusion-specific antigenic site Ø antibodies as well as of antibodies targeting other epitopes in virus neutralization. However, vaccination of cotton rats with FI-RSV specifically resulted in the induction of weakly neutralizing, antigenic site I-specific antibodies, which may play a role in the enhancement of disease observed after vaccination with such preparations.
针对呼吸道合胞病毒(RSV)融合(F)蛋白的抗体在针对这种重要呼吸道病毒的保护性免疫反应中发挥重要作用。然而,对于感染或接种RSV疫苗后诱导产生的针对多个F特异性表位的抗体水平了解甚少,而这对于指导(新型)疫苗的评估很重要。在本研究中,我们分析了人血清以及接种疫苗和经实验感染的棉鼠血清中针对RSV蛋白和F特异性表位的抗体水平及其与病毒中和作用的相关性。对人血清的分析显示,个体之间针对F、G(附着)和F特异性表位的抗体水平存在很大差异。对于识别融合前特异性抗原位点Ø的抗体,观察到与病毒中和作用的相关性最高。然而,我们的结果表明,靶向F蛋白其他部分的高水平抗体也可介导有效的抗病毒抗体反应。同样,经实验感染的棉鼠血清尽管缺乏抗原位点Ø特异性抗体,但仍具有高中和活性。令人惊讶的是,用福尔马林灭活的RSV(FI-RSV)进行疫苗接种仅导致诱导产生针对融合后特异性抗原位点I的低效中和抗体,尽管抗原位点I、II和IV在FI-RSV中有效展示。FI-RSV中抗原位点I明显的免疫显性可能解释了接种和攻毒后中和抗体水平较低的原因,并且可能在使用此类制剂观察到的疫苗诱导的疾病增强中起作用。
RSV是婴儿住院的重要原因。20世纪60年代使用FI-RSV疫苗制剂获得的灾难性结果导致疫苗诱导的疾病增强,这阻碍了RSV疫苗的开发。为了更好地了解感染或接种RSV疫苗后诱导产生的抗体库,我们研究了人和动物血清中针对融合(F)蛋白、附着(G)蛋白和F特异性表位的抗体水平。结果表明融合前特异性抗原位点Ø抗体以及靶向其他表位的抗体在病毒中和中的重要性。然而,用FI-RSV对棉鼠进行疫苗接种特别导致诱导产生低效中和的、抗原位点I特异性抗体,这可能在使用此类制剂接种后观察到的疾病增强中起作用。